# Clinical Core

> **NIH NIH P30** · UNIVERSITY OF WISCONSIN-MADISON · 2021 · $1,239,814

## Abstract

PROJECT SUMMARY - CLINICAL CORE (CORE B)
The primary objective of the Wisconsin Alzheimer's Disease Research Center's (ADRC) Clinical Core is to
provide investigators access to well-characterized, diverse patient and control populations and high-quality,
standardized clinical, cognitive, cerebrospinal fluid (CSF), serum/plasma, DNA, and neuroimaging data to
facilitate translational Alzheimer's disease (AD) research in preclinical diagnosis and early intervention. To that
end, the Core conducts comprehensive clinical evaluations in patients with mild cognitive impairment (MCI) and
mild dementia due to AD, cognitively normal older controls (OCN, >65 years), and middle-aged adults (IMPACT
cohort, 45-65 years) with varying levels of dementia risk based on family history. The Clinical Core team works
closely with all Cores to facilitate the Center's mission by participating in outreach and recruitment activities to
diverse communities; conducting standardized clinical and cognitive assessments of Core participants; gathering
ancillary aging-related cognitive and clinical data, including a detailed vascular risk assessment; collecting high-
quality blood, CSF, and DNA biospecimens; coordinating biospecimen collection with neuroimaging; completing
standardized data reporting in a timely manner; conducting skin biopsies for acquisition of induced pluripotent
stem cell (iPSC) lines; consenting Core participants for brain autopsy; facilitating cognitive testing and CSF
collection within investigator-initiated studies; and ensuring timely availability of participants, data, and
biospecimens to researchers locally and beyond. In the next grant cycle, the Core will accomplish the following
aims: Aim 1: Continue to recruit and retain cognitively unimpaired adults (IMPACT and OCN) and patients
with MCI for detailed annual (MCI, OCN) or biennial (IMPACT) clinical assessments (including standardized
Uniform Data Set [UDS] data and blood samples) and for biennial (MRI, CSF) and baseline (PET in subset)
biomarker assessments to support translational research in preclinical dementia. Aim 2: Continue to recruit and
retain patients with mild dementia due to AD for detailed annual clinical and blood biomarker assessments
(including standardized UDS data) and optional additional baseline biomarker assessments (MRI, CSF, PET).
Aim 3: Continue to integrate culturally-tailored outreach, education, and clinical services to diverse
communities to raise awareness of brain health and encourage long-term research engagement (including
clinical and biomarker assessments) and advocacy in underrepresented minority communities. Aim 4: Continue
to obtain consents for brain donation to support clinical-pathologic research and collect CSF, blood, DNA, and
iPSCs for translational research on preclinical markers of MCI and AD dementia. Aim 5: Continue to provide
infrastructure, resources, and services to facilitate collaborative research in normal cognitive aging, preclinical
dementia, ...

## Key facts

- **NIH application ID:** 10124259
- **Project number:** 5P30AG062715-03
- **Recipient organization:** UNIVERSITY OF WISCONSIN-MADISON
- **Principal Investigator:** CYNTHIA M CARLSSON
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,239,814
- **Award type:** 5
- **Project period:** 2019-05-01 → 2024-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10124259

## Citation

> US National Institutes of Health, RePORTER application 10124259, Clinical Core (5P30AG062715-03). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10124259. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*